B. Brauchle

P06.07 IN VIVO STUDIES OF IMMUNOMODULATORY A-CTLA-4 ANTIBODY IN A HUMANIZED MOUSE MODEL

M. Subklewe, S. Kobold, A. Gottschlich, 2021 .

Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia

Matthew J. Rardin, K. Metzeler, K. Spiekermann, 2020, Molecular Cancer Therapeutics.

Characterization of a Novel FLT3 BiTE® Antibody Construct for the Treatment of Acute Myeloid Leukemia

Matthew J. Rardin, K. Metzeler, K. Spiekermann, 2020 .

Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.

K. Metzeler, K. Spiekermann, M. Subklewe, 2018, Blood.

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression

M. von Bergwelt-Baildon, M. Subklewe, V. Bücklein, 2021, Frontiers in Immunology.

A modular and controllable T cell therapy platform for acute myeloid leukemia

C. Klein, S. Endres, M. Subklewe, 2021, Leukemia.

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

B. Vick, I. Jeremias, R. Kischel, 2022, Blood.

CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

K. Spiekermann, R. Kischel, S. Theurich, 2023, Cancer Immunology, Immunotherapy.